早期原发性胆汁性胆管炎进展与结局的相关因素
基于全球PBC研究组1615例早期PBC患者数据,中位随访7.9年,约半数患者在5年内进展至中度PBC,进展与临床事件风险升高相关。
要点
- 早期PBC患者5年内进展至中度PBC的比例为45.8%。
- 从中度进展至晚期PBC的5年比例为16.0%。
- 早期至中度及中度至晚期进展均与临床事件风险升高相关。
核心结论
- 约半数早期PBC患者在5年内进展至更严重阶段,进展与临床事件风险升高相关,对早期PBC患者进行监测很重要。
研究设计与样本
- 研究从全球PBC研究组数据库(含北美和欧洲19个肝病中心)纳入1615例早期PBC患者,平均年龄55.4岁,中位随访7.9年。
主要发现
- 1615例早期PBC患者中,904例进展为中度PBC,201例进展为晚期PBC。
- 1年、3年、5年进展至中度PBC的比例分别为12.9%、30.2%、45.8%。
- 随后1年、3年、5年进展至晚期PBC的比例分别为3.4%、12.5%、16.0%。
- 随访期间236例患者发生临床事件;中度PBC患者1年、3年、5年无事件生存率分别为97.9%、95.1%、91.5%,晚期PBC患者分别为90.6%、71.2%、58.3%。
- 早期进展至中度PBC及中度进展至晚期PBC与临床事件概率升高相关(时依HR 3.0,95%CI 2.0-4.5;时依HR 4.6,95%CI 3.5-6.2)。
关键数值与推荐
- 与早期进展至中度PBC相关的变量包括基线胆红素、白蛋白和碱性磷酸酶水平、AST/ALT比值、血小板计数及熊去氧胆酸治疗。
临床怎么用
- 对早期PBC患者进行监测很重要。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an early stage, based on biochemical analyses. We investigated the proportion of patients who progress to moderate or advanced PBC and factors associated with progression and patient survival. METHODS: We obtained data from 1615 patients (mean age, 55.4 y) with early stage PBC (based on their normal levels of albumin and bilirubin), collected at the time of initial evaluation or treatment, from the Global PBC Study Group database (comprising patients at 19 liver centers in North American and European countries). We collected data from health care evaluations on progression to moderate PBC (abnormal level of bilirubin or albumin) or advanced-stage PBC (abnormal level of both). The median follow-up time was 7.9 years. The composite end point was decompensation, hepatocellular carcinoma, liver transplantation, or death. RESULTS: Of the 1615 patients identified with early stage PBC, 904 developed moderate PBC and 201 developed advanced disease over the study period. The proportions of patients who transitioned to moderate PBC at 1, 3, and 5 years were 12.9%, 30.2%, and 45.8%. The proportions of these patients who then transitioned to advanced PBC at 1, 3, and 5 years later were 3.4%, 12.5%, and 16.0%, respectively. During the follow-up period, 236 patients had a clinical event. The proportions of patients with moderate PBC and event-free survival were 97.9%, 95.1%, and 91.5% at 1, 3, and 5 years, respectively, and the proportions of patients with advanced PBC and event-free survival were 90.6%, 71.2%, and 58.3% at 1, 3, and 5 years later, respectively. Variables associated with transition from early to moderate PBC included baseline levels of bilirubin, albumin, and alkaline phosphatase; aspartate to alanine aminotransferase ratio; platelet count; and treatment with ursodeoxycholic acid. Transitions from early to moderate PBC and from moderate to advanced PBC were associated with higher probabilities of a clinical event (time-dependent hazard ratios, 3.0; 95% CI, 2.0-4.5; and 4.6; 95% CI, 3.5-6.2). CONCLUSIONS: Approximately half of patients with early stage PBC progress to a more severe stage within 5 years. Progression is associated with an increased risk of a clinical event, so surveillance is important for patients with early stage PBC.
引用
- Gatselis NK, Goet JC, Zachou K, et al. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2019. PMID: 31419573. doi:10.1016/j.cgh.2019.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。